Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $33.62 +2.93 (+9.55%) (As of 09/5/2024 ET) Add Compare Share Share Today's Range$31.05▼$33.6950-Day Range$26.20▼$33.6252-Week Range$19.50▼$45.58Volume1.97 million shsAverage Volume1.14 million shsMarket Capitalization$4.91 billionP/E RatioN/ADividend YieldN/APrice Target$48.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunovant alerts: Email Address Immunovant MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.0% Upside$48.40 Price TargetShort InterestBearish19.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 7 Articles This WeekInsider TradingSelling Shares$904,638 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.43) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 starsMedical Sector790th out of 909 stocksBiological Products, Except Diagnostic Industry136th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has only been the subject of 3 research reports in the past 90 days.Read more about Immunovant's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.77% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 9.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 2.2 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Immunovant this week, compared to 5 articles on an average week.Search Interest14 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $904,638.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.43) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -17.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -17.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Immunovant Stock (NASDAQ:IMVT)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More IMVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesSeptember 2, 2024 | finance.yahoo.comAre Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?August 30, 2024 | americanbankingnews.comQ2 2025 EPS Estimates for Immunovant, Inc. (NASDAQ:IMVT) Cut by AnalystSeptember 6, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportunity. August 27, 2024 | benzinga.comImmunovant (NASDAQ:IMVT) Stock Quotes, Forecast and News SummaryAugust 19, 2024 | markets.businessinsider.comBuy Rating Backed by Batoclimab’s Promising Efficacy in Graves’ Disease TrialsAugust 15, 2024 | uk.investing.comImmunovant directors elected, auditor ratified by stockholdersAugust 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunovant Amidst Positive Clinical Advancements and Strong Market ProspectsAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immunovant’s Advancing Pipeline and Strategic Focus on Autoimmune DiseasesSeptember 6, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportunity. August 7, 2024 | markets.businessinsider.comImmunovant’s Strong Clinical Pipeline and Strategic Positioning Justify Buy RatingJuly 28, 2024 | investing.comImmunovant executive sells over $111k in company stockJuly 28, 2024 | investing.comImmunovant executive sells $95.9k in company stockJune 28, 2024 | seekingalpha.comImmunovant: Overvalued Amidst M&A SpeculationJune 27, 2024 | seekingalpha.comImmunovant: Next Generation Anti-FcRn Candidate Keeps Hopes AliveMay 29, 2024 | globenewswire.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024May 29, 2024 | markets.businessinsider.comBiohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage StudyMay 29, 2024 | investing.comImmunovant (IMVT) Earnings Dates & ReportsMay 19, 2024 | morningstar.comImmunovant Inc IMVTSee More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/06/2024Next Earnings (Estimated)11/14/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$48.40 High Stock Price Target$57.00 Low Stock Price Target$40.00 Potential Upside/Downside+44.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-259,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.07% Return on Assets-48.25% Debt Debt-to-Equity RatioN/A Current Ratio13.09 Quick Ratio13.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.72 per share Price / Book9.04Miscellaneous Outstanding Shares146,180,000Free Float137,555,000Market Cap$4.91 billion OptionableOptionable Beta0.67 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 45)M.D., Executive Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 56)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 60)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., Vice President of Investor RelationsMr. Mark S. Levine (Age 51)Chief Legal Officer & Corporate Secretary Ms. Lauren Schrier M.B.A.Vice President of MarketingMs. Christine BlodgettVice President of Human ResourcesDr. Julia G. Butchko Ph.D. (Age 53)Chief Development Officer Comp: $531kMore ExecutivesKey CompetitorsVivint Smart HomeNYSE:VVNTUtz BrandsNYSE:UTZAdvantage SolutionsNASDAQ:ADVChurchill Capital Corp IVNYSE:CCIVHyliionNYSE:HYLNView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 69,278 shares on 8/16/2024Ownership: 0.083%AQR Capital Management LLCSold 2,315 shares on 8/15/2024Ownership: 0.059%Blue Owl Capital Holdings LPSold 20,000 shares on 8/15/2024Ownership: 0.055%The Manufacturers Life Insurance Company Sold 39,877 shares on 8/15/2024Ownership: 0.026%Scientech Research LLCBought 12,634 shares on 8/15/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $42.13 on January 1st, 2024. Since then, IMVT stock has decreased by 20.2% and is now trading at $33.62. View the best growth stocks for 2024 here. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $0.07. Who are Immunovant's major shareholders? Immunovant's top institutional shareholders include Armistice Capital LLC (2.32%), First Turn Management LLC (0.48%), Fred Alger Management LLC (0.42%) and Logos Global Management LP (0.39%). Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Frank Torti, Eva Renee Barnett, Mark S Levine, William L Macias, Jay S Stout and Michael Geffner. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV) and Alibaba Group (BABA). This page (NASDAQ:IMVT) was last updated on 9/6/2024 by MarketBeat.com Staff From Our PartnersThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredYour Crypto Future is at StakeThe biggest names in finance are pouring billions into crypto… But here's the secret… Retail investors l...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts